Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person26
Braveheart Bio, Inc.
Company
GRI Bio, Inc.
Company
Q32 Bio Inc.
Company
Inmune Bio, Inc.
Company
KALA BIO, Inc.
Company
TELA Bio, Inc.
Company
TRex Bio, Inc.
Company
Instil Bio, Inc.
Company
Korro Bio, Inc.
Company
Climb Bio, Inc.
Company
Braze, Inc.
Company
BiomX Inc.
Company
BELITE BIO, INC
Company
Adicet Bio, Inc.
Company
KYNTRA BIO, INC.
Company
Valion Bio, Inc.
Company
BIOGEN INC.
Company
BIOVIE INC.
Company
ADAPTIN BIO, INC.
Company
Passage BIO, Inc.
Company
Annovis Bio, Inc.
Company
MUSTANG BIO, INC.
Company
BioAtla, Inc.
Company
iBio, Inc.
Company
BRC Inc.
Company
BRP Inc.
Company
Primary record4
Braveheart Bio, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On November 6, 2026, Braveheart Bio, Inc. (the “Company”) issued a press release titled “Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Stu
Braveheart Bio, Inc. filed SCHEDULE 13G
0000315066-26-002715.txt : 20261105 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0000315066 XXXXXXXX LIVE COMMON STOCK 09/30/2026 0002131524 BRAVEHEART BIO INC 10567X101 ONE LETTERMAN DR BLDG. A, STE. A4-300 SAN FRA
Braveheart Bio, Inc. filed SCHEDULE 13D/A
(the "SEC") on August 18, 2026. This Amendment No. 1 is being filed to report that the percentage of outstanding shares of common stock of the Issuer, par value $0.0001 per share ("Shares") that the Reporting Persons may
Braveheart Bio, Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On September 8, 2026, Braveheart Bio, Inc. (the Company ) announced its financial results and business highlights for the quarter ended June 30, 2026. A copy of th